Results 11 to 20 of about 16,020 (148)

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy. [PDF]

Allergy
Dupilumab in combination with OIT was well tolerated in children and adolescent patients with peanut allergy, and safety was consistent with the known dupilumab safety profile. A greater number of patients passed a DBPCFC during the OIT up‐dosing period with continuous dupilumab + OIT treatment versus continuous OIT.
Chinthrajah RS, Sindher SB, Nadeau KC, Leflein JG, Spergel JM, Petroni DH, Jones SM, Casale TB, Wang J, Carr WW, Shreffler WG, Wood RA, Wambre E, Liu J, Akinlade B, Atanasio A, Orengo JM, Hamilton JD, Kamal MA, Hooper AT, Patel K, Laws E, Mannent LP, Adelman DC, Ratnayake A, Radin AR.   +25 more
europepmc   +2 more sources

The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib

Clinical and Translational Medicine, Volume 13, Issue 4, April 2023., 2023
Activation of WNK1 associates to a worse ovarian cancer patient outcome. WNK1 signals cell proliferation through the ERK5 pathway. Trametinib provokes activation of the WNK1–ERK5 pathway. Combining trametinib with ERK5 route inhibitors may improve patients’ outcome.
Adrián Sánchez‐Fdez, Sofía Matilla‐Almazán, Juan Carlos Montero, Sofía Del Carmen, Mar Abad, Sara García‐Alonso, Somshuvra Bhattacharya, Kristin Calar, Pilar de la Puente, Alberto Ocaña, Atanasio Pandiella, Azucena Esparís‐Ogando   +11 more
wiley   +1 more source

Microglial Extracellular Vesicles Mediate C1q Deposition at the Pre-Synapse and Promote Synaptic Pruning. [PDF]

J Extracell Vesicles
Microglial EVs deliver C1q to pre‐synapses and promote synaptic pruning in vitro. C9orf72 KO microglia release more C1q‐storing EVs compared to WT and engulf more synapses in the hippocampus during the pruning period. Production of C1q‐storing EVs from WT microglia temporally correlates with the pruning period during postnatal development. ABSTRACT C1q
D'Arrigo G, Cutugno G, Golia MT, Sironi F, Lombardi M, Colombo SF, Frigerio R, Cretich M, Gagni P, Battocchio E, Barone C, Azzoni E, Bellini S, Saraceno C, Ghidoni R, Bendotti C, Paolicelli RC, Gabrielli M, Verderio C.   +18 more
europepmc   +2 more sources

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer

Journal of Cellular and Molecular Medicine, Volume 24, Issue 5, Page 3117-3127, March 2020., 2020
Abstract Identification of druggable vulnerabilities is a main objective in triple‐negative breast cancer (TNBC), where no curative therapies exist. Gene set enrichment analyses (GSEA) and a pharmacological evaluation using a library of compounds were used to select potential druggable combinations.
Verónica Corrales‐Sánchez, María del Mar Noblejas‐López, Cristina Nieto‐Jiménez, Javier Pérez‐Peña, Juan Carlos Montero, Miguel Burgos, Eva M. Galán‐Moya, Atanasio Pandiella, Alberto Ocaña   +8 more
wiley   +1 more source

Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma

Oxidative Medicine and Cellular Longevity, Volume 2019, Issue 1, 2019., 2019
Glioblastoma (GBM) is the most common and devastating primary brain tumor. The presence of cancer stem cells (CSCs) has been linked to their therapy resistance. Molecular and cellular components of the tumor microenvironment also play a fundamental role in the aggressiveness of these tumors.
Esther Hernández-SanMiguel, Ricardo Gargini, Teresa Cejalvo, Berta Segura-Collar, Paula Núñez-Hervada, Rafael Hortigüela, Juan M. Sepúlveda-Sánchez, Aurelio Hernández-Laín, Angel Pérez-Núñez, Eduardo Sanz, Pilar Sánchez-Gómez, Ana S. Fernandes   +11 more
wiley   +1 more source

Deficient spindle assembly checkpoint in multiple myeloma.

PLoS ONE, 2011
Multiple myeloma (MM) is a hematological disease characterized by an abnormal accumulation of plasma cells in the bone marrow. These cells have frequent cytogenetic abnormalities including translocations of the immunoglobulin heavy chain gene and ...
Elena Díaz-Rodríguez, Stela Álvarez-Fernández, Xi Chen, Bruno Paiva, Ricardo López-Pérez, Juan Luis García-Hernández, Jesús F San Miguel, Atanasio Pandiella   +7 more
doaj   +1 more source

The immunoglobulin‐like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation

Molecular Oncology, Volume 12, Issue 7, Page 1061-1076, June 2018., 2018
Ig‐like region of neuregulins (NRGs) is important in their capability to activate ErbB/HER receptors and mitogenic responses. A mutant lacking the Ig‐like domain fails to efficiently activate HER receptors, signaling pathways, and cell proliferation when compared to wild‐type NRG.
Ariana Centa, Ruth Rodríguez‐Barrueco, Juan Carlos Montero, Atanasio Pandiella   +3 more
wiley   +1 more source

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

Haematologica, 2010
Background Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma.
Enrique M. Ocio, David Vilanova, Peter Atadja, Patricia Maiso, Edvan Crusoe, Diego Fernández-Lázaro, Mercedes Garayoa, Laura San-Segundo, Teresa Hernández-Iglesias, Enrique de Álava, Wenlin Shao, Yung-Mae Yao, Atanasio Pandiella, Jesús F. San-Miguel   +13 more
doaj   +1 more source

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications

Molecular Oncology, Volume 11, Issue 12, Page 1788-1805, December 2017., 2017
Understanding the mechanisms involved in breast cancer dissemination is essential for the development of new therapeutic strategies to prevent metastasis and improve patient outcome. Our studies describe that the prometastatic neuregulin–MMP13 axis is regulated by SRC family kinases. Moreover, the clinically approved tyrosine kinase inhibitor dasatinib
Ana Orive‐Ramos, Samuel Seoane, Alberto Ocaña, Atanasio Pandiella, Juan Carlos Montero   +4 more
wiley   +1 more source

The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

Haematologica, 2008
Background Proteasome inhibition represents a promising novel anticancer therapy, and bortezomib is a highly selective reversible inhibitor of the proteasome complex.
Enrique Colado, Stela Álvarez-Fernández, Patricia Maiso, Jesús Martín-Sánchez, Maria Belén Vidriales, Mercedes Garayoa, Enrique M. Ocio, Juan Carlos Montero, Atanasio Pandiella, Jesús F. San Miguel   +9 more
doaj   +1 more source